News

A team led by a University of Washington (UW) School of Medicine scientist will use a $17.2 million National Institute on Aging (NIA) grant to study whether degenerative eye diseases are linked to Alzheimer’s disease (AD). The award went to Cecilia Lee, an assistant professor of ophthalmology. Along…

A natural compound with antioxidative properties that might help to delay the onset of neurodegenerative diseases like Alzheimer’s can now be produced in baker’s yeast, a study reports. This new way of producing ergothioneine, as the compound is known, may lead to a commercially viable new treatment for people…

Expanding their existing relationship, Seniorlink and Humana are offering a program that provides additional care management and support to families caring for individuals with dementia, including Alzheimer’s disease. The dementia management program, which covers Humana Medicare Advantage members, capitalizes on Seniorlink’s experience and expertise in supporting caregivers. Specifically,…

Laying the foundation for what could be a pivotal clinical trial into Alzheimer’s (AD) detection, Optina Diagnostics and Wagner Macula & Retina Center will collaborate on a “real-world” study aimed at advancing Optina’s retinal deep phenotyping platform. “It brings together a whole new paradigm for the way we…

A Phase 2b study of oral neflamapimod in treating mild Alzheimer’s disease met its secondary goals of statistically significant drops in phospho-tau and tau protein levels in the cerebrospinal fluid (CSF) of treated patients compared to those given a placebo, EIP Pharma announced. But the trial failed to show evidence of…

EastGate announced plans to expand its liquid insulin delivery platforms, used to treat type 2 diabetes, for use in a possible pilot trial in people with early onset Alzheimer’s disease. “Alzheimer’s disease, along with diabetes, is growing at a rapid pace and simple and effective solutions with existing proteins could…

An experimental vaccine targeting the toxic form of tau protein reduced cellular tangles in the brain — a hallmark of Alzheimer’s — and eased behavioral and motor defects in a mouse model of the disease, a study showed. By generating high levels of anti-tau antibodies, this vaccine…

T3D Therapeutics has secured the needed funding to move forward with its Phase 2 trial testing T3D-959 as a potential treatment for people with mild-to-moderate Alzheimer’s disease. The total funding includes $15 million from an investor, in addition to a $9 million award from the…

Efforts are underway this month to focus attention on Alzheimer’s (AD), a disease that, along with other forms of dementia, affects some 44 million people globally and is rapidly growing in prevalence. During November in the U.S., Alzheimer’s Awareness Month observances include online tributes to caregivers, listings of…

Oligomannate (GV-971), a compound derived from marine brown algae that promotes a healthy gut microbiome, is now conditionally approved in China to treat mild to moderate Alzheimer’s disease (AD), making it the first new disease therapy approved anywhere since Allergan’s Namenda (memantine) in late 2003. The decision was…